Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer
The PACIFIC-2 Phase III trial for Imfinzi (durvalumab) concurrently administered with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of progression-free survival (PFS) versus CRT alone for the treatment…
Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer
AstraZeneca’s Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine and cisplatin). Imfinzi…
REGENERON COMMITS $34 MILLION OVER FIVE YEARS TO CONTINUE TO SPONSOR THE REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR (ISEF)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (Society) today announced that Regeneron is increasing and extending its commitment as the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), the world’s…
GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia
GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of momelotinib…
Bayer Foundation presents Science Awards
This year the Bayer Foundation is presenting their renowned Hansen Family Award to Professor Claudia Höbartner. The Hansen Family Award is presented alternating with the Otto Bayer Award every second year.…
Bayer collaboration with Microsoft connects farm data to address lack of data interoperability in agriculture
Bayer today announced at Agritechnica, the world’s leading trade fair for agricultural machinery, an update on the strategic collaboration with Microsoft: New data connectors allow secure, compliant exchange of farm…
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today presented first-in-human data from a Phase 1 trial investigating AB-1002…
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark Novo Nordisk today announced plans to invest more than 42 billion Danish kroner…
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys®…
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide…
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial Positive high-level results from the EMERALD-1 Phase III trial showed…
Bayer and Recursion focus research collaboration on Oncology
Bayer and Recursion focus research collaboration on Oncology Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have…